Close Menu

NEW YORK – HTG Molecular Diagnostics reported after the close of the market on Tuesday that its third quarter revenues grew 15 percent year over year as product-related revenues more than offset a decline in collaborative revenues.

The company also said that it has terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments, causing HTG to also reduce its full-year 2019 revenue guidance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.